肺癌化疗前后CEA、CYFRA21-1和NSE水平变化及其临床意义

目的探讨紫杉醇类或VP-16联合顺铂治疗肺癌前后肿瘤标记物的变化对于肺癌化疗效果评价的价值。方法38例肺癌经2个疗程的紫杉醇类或VP-16联合顺铂方案化疗后，检测不同病理类型组第1次化疗前和第3次化疗前肿瘤标记物CEA、CYFRA21-1、NSE的变化，并根据CT等影像学结果的化疗前后改变来进行对比分析。结果2次化疗后CEA、CYFRA21-1、NSE水平较化疗前减低，其中CEA对于肺腺癌，CYFRA-21-1对于肺鳞癌，NSE对于小细胞肺癌化疗后效果的评定具有一定价值。结论通过监测肿瘤标记物CEA、CYFRA21-1和NSE水平改变可以协助肺癌化疗后疗效的判断，具有简便、经济的特点，在临床中具有一定的价值。

Changes of levels of CEA,CYFRA21 - 1 and NSE in patients with lung cancer before and after chemotherapy and its clinical significance

Objective To investigate the value of tumor markers changes in evaluation of effects of chemotherapy in patients with lung cancer. Methods Thirty eight patients with lung cancer were given 2 periods of chemotherapy of TP（Taxol ＋ DDP） or EP（ VP - 16 ＋ DDP）. Before the first and the third chemotherapy, the tumor markers changes of CEA, CYFRA21 - 1 and NSE and the changes of Chest CT were recorded. Results After the secend chemotherapy the levels of tumor markers apperently reduced, there were statistically difference compared with the value of the first chemotherapy. The changes of CEA in lung adenocarcinoma patients were valuable and so did CYFRA21 - 1 in lung squamous cell carcinomas patients and NSE in small lung cancer patients. Conclusion Monitoring on CEA, CYFRA21 - 1 and NSE could help evaluate the effects of postchemotherapy in patients with lung cancer, which is simple and cost-effective.